[S02DA03, antipyrine, The risk or severity of adverse effects can be increased when Antipyrine is combined with Alendronic acid.]
[J01GA01, streptomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Alendronic acid.]
[J01EC01, sulfamethoxazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Sulfamethoxazole.]
[M01AB02, sulindac, The risk or severity of adverse effects can be increased when Sulindac is combined with Alendronic acid.]
[M01AX04, apazone, The risk or severity of adverse effects can be increased when Azapropazone is combined with Alendronic acid.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Alendronic acid.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftaroline fosamil is combined with Alendronic acid.]
[L04AX02, thalidomide, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Alendronic acid.]
[B03AB03, sodium ironedetate, Sodium feredetate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AA12, tobramycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tobramycin is combined with Alendronic acid.]
[M02AA21, tolmetin, The risk or severity of adverse effects can be increased when Tolmetin is combined with Alendronic acid.]
[S01BA05, triamcinolone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Alendronic acid.]
[C03DB02, triamterene, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Triamterene is combined with Alendronic acid.]
[N05CD05, triazolam, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Triazolam.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Alendronic acid.]
[S01AA28, vancomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Alendronic acid.]
[L01CA02, vincristine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Alendronic acid.]
[J05AF01, zidovudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Alendronic acid.]
[J05AE02, indinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Alendronic acid.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Alendronic acid.]
[M05BA05, tiludronic acid, The risk or severity of adverse effects can be increased when Alendronic acid is combined with Tiludronic acid.]
[A02BC04, rabeprazole, The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Rabeprazole.]
[M05BA06, ibandronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ibandronate.]
[N02BA01, aspirin, The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alendronic acid.]
[S01LA05, aflibercept, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Aflibercept is combined with Alendronic acid.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Bacitracin is combined with Alendronic acid.]
[M03BX01, baclofen, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Alendronic acid.]
[A02AA05, magnesium silicate, The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium silicate.]
[A02AC02, calcium silicate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium silicate.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Alendronic acid.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Alendronic acid.]
[L04AX06, pomalidomide, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Alendronic acid.]
[N02BA10, benorilate, The risk or severity of adverse effects can be increased when Benorilate is combined with Alendronic acid.]
[A12CC09, magnesium orotate, Magnesium orotate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AH01, celecoxib, The risk or severity of adverse effects can be increased when Celecoxib is combined with Alendronic acid.]
[A12CC05, magnesium aspartate, Magnesium aspartate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R02AX03, benzydamine, The risk or severity of adverse effects can be increased when Benzydamine is combined with Alendronic acid.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Alendronic acid.]
[B03AB04, ferric hydroxide, Ferric hydroxide can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AE05, sucroferric oxyhydroxide, Iron sucrose can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03BA03, betamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Betamethasone is combined with Alendronic acid.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Bezafibrate.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Dihydrostreptomycin is combined with Alendronic acid.]
[V03AE08, ferric citrate, Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03AA06, gentamicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Gentamicin is combined with Alendronic acid.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Adefovir dipivoxil is combined with Alendronic acid.]
[A06AD03, magnesium peroxide, The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium peroxide.]
[M02AA25, aceclofenac, The risk or severity of adverse effects can be increased when Aceclofenac is combined with Alendronic acid.]
[M01AB11, acemetacin, The risk or severity of adverse effects can be increased when Acemetacin is combined with Alendronic acid.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Acipimox.]
[A02BC03, lansoprazole, The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole.]
[L01CX01, trabectedin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Trabectedin.]
[J05AF13, tenofovir alafenamide, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir alafenamide is combined with Alendronic acid.]
[M01AE16, alminoprofen, The risk or severity of adverse effects can be increased when Alminoprofen is combined with Alendronic acid.]
[A02AB06, aloglutamol, The serum concentration of Alendronic acid can be decreased when it is combined with Aloglutamol.]
[A02AD05, aluminum magnesium silicate, The serum concentration of Alendronic acid can be decreased when it is combined with Almasilate.]
[A02AB03, aluminum phosphate, The serum concentration of Alendronic acid can be decreased when it is combined with Aluminium phosphate.]
[C03CA02, bumetanide, The risk or severity of hypocalcemia can be increased when Bumetanide is combined with Alendronic acid.]
[M02AA03, clofezone, The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Rabeprazole.]
[A07EC04, balsalazide, The risk or severity of adverse effects can be increased when Balsalazide is combined with Alendronic acid.]
[G04BA03, calcium chloride, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium chloride.]
[D11AX03, calcium gluconate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium gluconate.]
[L04AB02, infliximab, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Alendronic acid.]
[A12AA01, calcium phosphate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium Phosphate.]
[P01AX10, fumagillin, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Alendronic acid.]
[A02BX12, bismuth subnitrate, The serum concentration of Alendronic acid can be decreased when it is combined with Bismuth subnitrate.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefprozil is combined with Alendronic acid.]
[M01AB07, bumadizone, The risk or severity of adverse effects can be increased when Bumadizone is combined with Alendronic acid.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Captopril.]
[A06AC08, calcium polycarbophil, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium polycarbophil.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Alendronic acid.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefepime is combined with Alendronic acid.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefetamet is combined with Alendronic acid.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefodizime is combined with Alendronic acid.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceforanide is combined with Alendronic acid.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpodoxime is combined with Alendronic acid.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftibuten is combined with Alendronic acid.]
[J01GB14, plazomicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Plazomicin is combined with Alendronic acid.]
[M01AC05, lornoxicam, The risk or severity of adverse effects can be increased when Lornoxicam is combined with Alendronic acid.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Inotersen is combined with Alendronic acid.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ciprofibrate.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ubidecarenone.]
[V03AE07, calcium acetate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium acetate.]
[A12CC06, magnesium lactate, Magnesium lactate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaclor is combined with Alendronic acid.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefadroxil is combined with Alendronic acid.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefamandole is combined with Alendronic acid.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefatrizine is combined with Alendronic acid.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefazolin is combined with Alendronic acid.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefmetazole is combined with Alendronic acid.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefonicid is combined with Alendronic acid.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoperazone is combined with Alendronic acid.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Alendronic acid.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotetan is combined with Alendronic acid.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotiam is combined with Alendronic acid.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoxitin is combined with Alendronic acid.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefsulodin is combined with Alendronic acid.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Alendronic acid.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftizoxime is combined with Alendronic acid.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftriaxone is combined with Alendronic acid.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefuroxime is combined with Alendronic acid.]
[S01LA06, brolucizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Alendronic acid.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Alendronic acid.]
[J01DB01, cephalexin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephalexin is combined with Alendronic acid.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaloridine is combined with Alendronic acid.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefalotin is combined with Alendronic acid.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefapirin is combined with Alendronic acid.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefradine is combined with Alendronic acid.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Givosiran is combined with Alendronic acid.]
[M01AH02, rofecoxib, The risk or severity of adverse effects can be increased when Rofecoxib is combined with Alendronic acid.]
[M05BA01, etidronic acid, The risk or severity of adverse effects can be increased when Alendronic acid is combined with Etidronic acid.]
[S01AA13, fusidic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Fusidic acid.]
[M01AC04, droxicam, The risk or severity of adverse effects can be increased when Droxicam is combined with Alendronic acid.]
[M02AA27, dexketoprofen, The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Alendronic acid.]
[P01BA01, chloroquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Alendronic acid.]
[N02BA07, ethenzamide, The risk or severity of adverse effects can be increased when Ethenzamide is combined with Alendronic acid.]
[M01AB08, etodolac, The risk or severity of adverse effects can be increased when Etodolac is combined with Alendronic acid.]
[M02AA06, etofenamate, The risk or severity of adverse effects can be increased when Etofenamate is combined with Alendronic acid.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Etofibrate.]
[M01AE05, fenbufen, The risk or severity of adverse effects can be increased when Fenbufen is combined with Alendronic acid.]
[V08CA07, ferric ammonium citrate, Ferric ammonium citrate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB31, prussian blue insoluble, Prussian blue can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AB02, iron sucrose, Iron sucrose can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA05, ferrous chloride, Ferrous chloride can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA02, ferrous fumarate, Ferrous fumarate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA03, ferrous gluconate, Ferrous gluconate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA06, ferrous succinate, Ferrous succinate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA07, ferrous sulfate, Ferrous sulfate anhydrous can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01LA08, bevacizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Alendronic acid.]
[B03AB10, ferric maltol, Ferric maltol can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Alendronic acid.]
[S03AA07, ciprofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Alendronic acid.]
[L01XA01, cisplatin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Alendronic acid.]
[M01AG01, mefenamic acid, The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Alendronic acid.]
[A12AA02, calcium glubionate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium glubionate anhydrous.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Clofibrate.]
[J01GB12, arbekacin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Alendronic acid.]
[M01AX13, proquazone, The risk or severity of adverse effects can be increased when Proquazone is combined with Alendronic acid.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Colchicine.]
[J01XB01, colistin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Colistin is combined with Alendronic acid.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpirome is combined with Alendronic acid.]
[L04AA13, leflunomide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Leflunomide.]
[A02AD04, hydrotalcite, The serum concentration of Alendronic acid can be decreased when it is combined with Hydrotalcite.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Alendronic acid.]
[B01AC10, indobufen, The risk or severity of adverse effects can be increased when Indobufen is combined with Alendronic acid.]
[M01AH03, valdecoxib, The risk or severity of adverse effects can be increased when Valdecoxib is combined with Alendronic acid.]
[M01AH04, parecoxib, The risk or severity of adverse effects can be increased when Parecoxib is combined with Alendronic acid.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Acyclovir is combined with Alendronic acid.]
[M01AA06, kebuzone, The risk or severity of adverse effects can be increased when Kebuzone is combined with Alendronic acid.]
[A02BC05, esomeprazole, The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Esomeprazole.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Nafarelin.]
[M01AB09, lonazolac, The risk or severity of adverse effects can be increased when Lonazolac is combined with Alendronic acid.]
[M02AA31, loxoprofen, The risk or severity of adverse effects can be increased when Loxoprofen is combined with Alendronic acid.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Loracarbef is combined with Alendronic acid.]
[A02AD02, magaldrate, The serum concentration of Alendronic acid can be decreased when it is combined with Magaldrate.]
[A06AD01, magnesium carbonate, The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium carbonate.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Mebeverine.]
[J05AF07, tenofovir disoproxil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Alendronic acid.]
[S01XA18, cyclosporine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Alendronic acid.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of adverse effects can be increased when Mofebutazone is combined with Alendronic acid.]
[M01AX22, morniflumate, The risk or severity of adverse effects can be increased when Morniflumate is combined with Alendronic acid.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Cytarabine.]
[M01AH05, etoricoxib, The risk or severity of adverse effects can be increased when Etoricoxib is combined with Alendronic acid.]
[M01AX01, nabumetone, The risk or severity of adverse effects can be increased when Nabumetone is combined with Alendronic acid.]
[A07EC03, olsalazine, The risk or severity of adverse effects can be increased when Olsalazine is combined with Alendronic acid.]
[M01AE12, oxaprozin, The risk or severity of adverse effects can be increased when Oxaprozin is combined with Alendronic acid.]
[S03BA01, dexamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Dexamethasone.]
[M05BA02, clodronic acid, The risk or severity of adverse effects can be increased when Alendronic acid is combined with Clodronic acid.]
[S01BC03, diclofenac, The risk or severity of adverse effects can be increased when Diclofenac is combined with Alendronic acid.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Foscarnet is combined with Alendronic acid.]
[C03CA03, piretanide, The risk or severity of hypocalcemia can be increased when Piretanide is combined with Alendronic acid.]
[N02BA11, diflunisal, The risk or severity of adverse effects can be increased when Diflunisal is combined with Alendronic acid.]
[L04AX04, lenalidomide, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Lenalidomide is combined with Alendronic acid.]
[J05AE08, atazanavir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Atazanavir is combined with Alendronic acid.]
[N02BB04, propyphenazone, The risk or severity of adverse effects can be increased when Propyphenazone is combined with Alendronic acid.]
[M01AB14, proglumetacin, The risk or severity of adverse effects can be increased when Proglumetacin is combined with Alendronic acid.]
[L01EX01, sunitinib, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Alendronic acid.]
[S01BC05, ketorolac, The risk or severity of adverse effects can be increased when Ketorolac is combined with Alendronic acid.]
[N02BA06, salsalate, The risk or severity of adverse effects can be increased when Salsalate is combined with Alendronic acid.]
[R03AC12, salmeterol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Salmeterol.]
[H05BA01, salmon calcitonin, The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Alendronic acid.]
[C10AA01, simvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Simvastatin.]
[B05XA02, sodium bicarbonate, The serum concentration of Alendronic acid can be decreased when it is combined with Sodium bicarbonate.]
[M01AC02, tenoxicam, The risk or severity of adverse effects can be increased when Tenoxicam is combined with Alendronic acid.]
[D01BA02, terbinafine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Terbinafine.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Alendronic acid.]
[M01AG02, tolfenamic acid, The risk or severity of adverse effects can be increased when Tolfenamic acid is combined with Alendronic acid.]
[C03CA04, torsemide, The risk or severity of hypocalcemia can be increased when Torasemide is combined with Alendronic acid.]
[M01AB04, zomepirac, The risk or severity of adverse effects can be increased when Zomepirac is combined with Alendronic acid.]
[L01XA02, carboplatin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Alendronic acid.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Iloprost.]
[A02BC02, pantoprazole, The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Pantoprazole.]
[C10AA04, fluvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Fluvastatin.]
[M01AC06, meloxicam, The risk or severity of adverse effects can be increased when Meloxicam is combined with Alendronic acid.]
[L04AD02, tacrolimus, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Alendronic acid.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Alendronic acid.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Alendronic acid.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Alendronic acid.]
[M01AE04, fenoprofen, The risk or severity of adverse effects can be increased when Fenoprofen is combined with Alendronic acid.]
[L04AA40, cladribine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Alendronic acid.]
[N02BG04, floctafenine, The risk or severity of adverse effects can be increased when Floctafenine is combined with Alendronic acid.]
[V03AZ01, ethanol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ethanol.]
[S01BC04, flurbiprofen, The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Alendronic acid.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Alendronic acid.]
[C03CA01, furosemide, The risk or severity of hypocalcemia can be increased when Furosemide is combined with Alendronic acid.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ganciclovir.]
[C10AB04, gemfibrozil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Gemfibrozil.]
[A12AA13, calcium citrate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium citrate.]
[A12AA10, calcium gluceptate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium glucoheptonate.]
[A12AA05, calcium lactate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium lactate.]
[A12AA30, calcium levulinate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium levulinate.]
[B05CB03, magnesium citrate, Magnesium citrate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC03, magnesium gluconate, Magnesium gluconate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A07EC02, mesalamine, The risk or severity of adverse effects can be increased when Mesalazine is combined with Alendronic acid.]
[M02AA26, nimesulide, The risk or severity of adverse effects can be increased when Nimesulide is combined with Alendronic acid.]
[C03AA03, hydrochlorothiazide, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hydrochlorothiazide is combined with Alendronic acid.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of adverse effects can be increased when Ibuprofen is combined with Alendronic acid.]
[L01CD01, paclitaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Paclitaxel.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Alendronic acid.]
[S01LA04, ranibizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Alendronic acid.]
[C10AA06, cerivastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Alendronic acid.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Stavudine.]
[J04AC01, isoniazid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Isoniazid.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Isotretinoin.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Alendronic acid.]
[S01AA24, kanamycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Kanamycin is combined with Alendronic acid.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Alendronic acid.]
[A02AB01, aluminum hydroxide, The serum concentration of Alendronic acid can be decreased when it is combined with Aluminum hydroxide.]
[M02AA10, ketoprofen, The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alendronic acid.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Alendronic acid is combined with Deferasirox.]
[M01AE11, tiaprofenic acid, The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Alendronic acid.]
[C03CC01, ethacrynic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Alendronic acid.]
[S01AA21, amikacin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amikacin is combined with Alendronic acid.]
[C10AA02, lovastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Alendronic acid.]
[B05XA11, magnesium chloride, Magnesium chloride can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G04BX01, magnesium hydroxide, The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, Magnesium sulfate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Alendronic acid.]
[M02AA18, meclofenamic acid, The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alendronic acid.]
[P01BC02, mefloquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Alendronic acid.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Lamivudine.]
[L04AX03, methotrexate, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Methotrexate is combined with Alendronic acid.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Methyldopa.]
[A03FA01, metoclopramide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Metoclopramide.]
[N02BB03, aminopyrine, The risk or severity of adverse effects can be increased when Aminophenazone is combined with Alendronic acid.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Minocycline.]
[C01BD01, amiodarone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Amiodarone.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Latamoxef is combined with Alendronic acid.]
[L01EX03, pazopanib, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Alendronic acid.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Raltegravir.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Naltrexone.]
[M02AA12, naproxen, The risk or severity of adverse effects can be increased when Naproxen is combined with Alendronic acid.]
[L01CD02, docetaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Letrozole.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Alendronic acid.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Alendronic acid.]
[S01AA23, netilmicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Netilmicin is combined with Alendronic acid.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Valaciclovir is combined with Alendronic acid.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Alendronic acid.]
[M02AA17, niflumic acid, The risk or severity of adverse effects can be increased when Niflumic acid is combined with Alendronic acid.]
[C02DD01, nitroprusside, Nitroprusside can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Norfloxacin.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ofloxacin.]
[A02BC01, omeprazole, The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Omeprazole.]
[M05BA08, zoledronic acid, The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Alendronic acid.]
[V08CB01, ferumoxsil, Ferumoxsil can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01BC02, oxyphenbutazone, The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alendronic acid.]
[J04AB30, capreomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Alendronic acid.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Alendronic acid.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Penicillamine.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Phenazopyridine is combined with Alendronic acid.]
[M02AA01, phenylbutazone, The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alendronic acid.]
[A02BC06, dexlansoprazole, The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole.]
[N03AB02, phenytoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Alendronic acid.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cidofovir is combined with Alendronic acid.]
[C10AA05, atorvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Atorvastatin.]
[J05AE01, saquinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Saquinavir.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Eprosartan.]
[S01BC06, piroxicam, The risk or severity of adverse effects can be increased when Piroxicam is combined with Alendronic acid.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefditoren is combined with Alendronic acid.]
[J05AE03, ritonavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Alendronic acid.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Pitavastatin.]
[C01BA02, procainamide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Procainamide.]
[L01XB01, procarbazine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Procarbazine.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Fenofibrate.]
[N01AX10, propofol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Propofol.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Alendronic acid.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Alendronic acid.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ranitidine.]
[N02BA05, salicylamide, The risk or severity of adverse effects can be increased when Salicylamide is combined with Alendronic acid.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alendronic acid.]
[S01BC08, salicylic acid, The risk or severity of adverse effects can be increased when Salicylic acid is combined with Alendronic acid.]
[J01GB08, sisomicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Sisomicin is combined with Alendronic acid.]
[A12AA11, calcium pangamate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium pangamate.]
[S02DA03, antipyrine, The risk or severity of adverse effects can be increased when Antipyrine is combined with Alendronic acid.]
[J01GA01, streptomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Streptomycin is combined with Alendronic acid.]
[J01EC01, sulfamethoxazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Sulfamethoxazole.]
[M01AB02, sulindac, The risk or severity of adverse effects can be increased when Sulindac is combined with Alendronic acid.]
[M01AX04, apazone, The risk or severity of adverse effects can be increased when Azapropazone is combined with Alendronic acid.]
[N06DA01, tacrine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Tacrine is combined with Alendronic acid.]
[J01DI02, ceftaroline fosamil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftaroline fosamil is combined with Alendronic acid.]
[L04AX02, thalidomide, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Thalidomide is combined with Alendronic acid.]
[B03AB03, sodium ironedetate, Sodium feredetate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AA12, tobramycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tobramycin is combined with Alendronic acid.]
[M02AA21, tolmetin, The risk or severity of adverse effects can be increased when Tolmetin is combined with Alendronic acid.]
[S01BA05, triamcinolone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Triamcinolone is combined with Alendronic acid.]
[C03DB02, triamterene, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Triamterene is combined with Alendronic acid.]
[N05CD05, triazolam, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Triazolam.]
[J01EA01, trimethoprim, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Trimethoprim is combined with Alendronic acid.]
[S01AA28, vancomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Vancomycin is combined with Alendronic acid.]
[L01CA02, vincristine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Vincristine is combined with Alendronic acid.]
[J05AF01, zidovudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Zidovudine is combined with Alendronic acid.]
[J05AE02, indinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Indinavir is combined with Alendronic acid.]
[M05BA03, pamidronic acid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Pamidronic acid is combined with Alendronic acid.]
[M05BA05, tiludronic acid, The risk or severity of adverse effects can be increased when Alendronic acid is combined with Tiludronic acid.]
[A02BC04, rabeprazole, The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Rabeprazole.]
[M05BA06, ibandronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ibandronate.]
[N02BA01, aspirin, The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Alendronic acid.]
[S01LA05, aflibercept, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Aflibercept is combined with Alendronic acid.]
[R02AB04, bacitracin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Bacitracin is combined with Alendronic acid.]
[M03BX01, baclofen, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Baclofen is combined with Alendronic acid.]
[A02AA05, magnesium silicate, The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium silicate.]
[A02AC02, calcium silicate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium silicate.]
[C08CA13, lercanidipine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lercanidipine is combined with Alendronic acid.]
[G04BE03, sildenafil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Sildenafil is combined with Alendronic acid.]
[L04AX06, pomalidomide, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pomalidomide is combined with Alendronic acid.]
[N02BA10, benorilate, The risk or severity of adverse effects can be increased when Benorilate is combined with Alendronic acid.]
[A12CC09, magnesium orotate, Magnesium orotate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AH01, celecoxib, The risk or severity of adverse effects can be increased when Celecoxib is combined with Alendronic acid.]
[A12CC05, magnesium aspartate, Magnesium aspartate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R02AX03, benzydamine, The risk or severity of adverse effects can be increased when Benzydamine is combined with Alendronic acid.]
[H05AA03, parathyroid hormone, The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Alendronic acid.]
[B03AB04, ferric hydroxide, Ferric hydroxide can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AE05, sucroferric oxyhydroxide, Iron sucrose can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03BA03, betamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Betamethasone is combined with Alendronic acid.]
[C10AB02, bezafibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Bezafibrate.]
[S01AA15, dihydrostreptomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Dihydrostreptomycin is combined with Alendronic acid.]
[V03AE08, ferric citrate, Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03AA06, gentamicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Gentamicin is combined with Alendronic acid.]
[J05AF08, adefovir dipivoxil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Adefovir dipivoxil is combined with Alendronic acid.]
[A06AD03, magnesium peroxide, The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium peroxide.]
[M02AA25, aceclofenac, The risk or severity of adverse effects can be increased when Aceclofenac is combined with Alendronic acid.]
[M01AB11, acemetacin, The risk or severity of adverse effects can be increased when Acemetacin is combined with Alendronic acid.]
[C10AD06, acipimox, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Acipimox.]
[A02BC03, lansoprazole, The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Lansoprazole.]
[L01CX01, trabectedin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Trabectedin.]
[J05AF13, tenofovir alafenamide, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir alafenamide is combined with Alendronic acid.]
[M01AE16, alminoprofen, The risk or severity of adverse effects can be increased when Alminoprofen is combined with Alendronic acid.]
[A02AB06, aloglutamol, The serum concentration of Alendronic acid can be decreased when it is combined with Aloglutamol.]
[A02AD05, aluminum magnesium silicate, The serum concentration of Alendronic acid can be decreased when it is combined with Almasilate.]
[A02AB03, aluminum phosphate, The serum concentration of Alendronic acid can be decreased when it is combined with Aluminium phosphate.]
[C03CA02, bumetanide, The risk or severity of hypocalcemia can be increased when Bumetanide is combined with Alendronic acid.]
[M02AA03, clofezone, The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Rabeprazole.]
[A07EC04, balsalazide, The risk or severity of adverse effects can be increased when Balsalazide is combined with Alendronic acid.]
[G04BA03, calcium chloride, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium chloride.]
[D11AX03, calcium gluconate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium gluconate.]
[L04AB02, infliximab, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Infliximab is combined with Alendronic acid.]
[A12AA01, calcium phosphate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium Phosphate.]
[P01AX10, fumagillin, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Fumagillin is combined with Alendronic acid.]
[A02BX12, bismuth subnitrate, The serum concentration of Alendronic acid can be decreased when it is combined with Bismuth subnitrate.]
[J01DC10, cefprozil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefprozil is combined with Alendronic acid.]
[M01AB07, bumadizone, The risk or severity of adverse effects can be increased when Bumadizone is combined with Alendronic acid.]
[C09AA01, captopril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Captopril.]
[A06AC08, calcium polycarbophil, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium polycarbophil.]
[H03BB01, carbimazole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Carbimazole is combined with Alendronic acid.]
[J01DE01, cefepime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefepime is combined with Alendronic acid.]
[J01DD10, cefetamet, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefetamet is combined with Alendronic acid.]
[J01DD09, cefodizime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefodizime is combined with Alendronic acid.]
[J01DC11, ceforanide, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceforanide is combined with Alendronic acid.]
[J01DD13, cefpodoxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpodoxime is combined with Alendronic acid.]
[J01DD14, ceftibuten, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftibuten is combined with Alendronic acid.]
[J01GB14, plazomicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Plazomicin is combined with Alendronic acid.]
[M01AC05, lornoxicam, The risk or severity of adverse effects can be increased when Lornoxicam is combined with Alendronic acid.]
[N07XX15, inotersen, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Inotersen is combined with Alendronic acid.]
[C10AB08, ciprofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ciprofibrate.]
[C01EB09, ubidecarenone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ubidecarenone.]
[V03AE07, calcium acetate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium acetate.]
[A12CC06, magnesium lactate, Magnesium lactate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01DC04, cefaclor, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaclor is combined with Alendronic acid.]
[J01DB05, cefadroxil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefadroxil is combined with Alendronic acid.]
[J01DC03, cefamandole, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefamandole is combined with Alendronic acid.]
[J01DB07, cefatrizine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefatrizine is combined with Alendronic acid.]
[J01DB04, cefazolin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefazolin is combined with Alendronic acid.]
[J01DC09, cefmetazole, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefmetazole is combined with Alendronic acid.]
[J01DC06, cefonicid, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefonicid is combined with Alendronic acid.]
[J01DD12, cefoperazone, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoperazone is combined with Alendronic acid.]
[J01DD01, cefotaxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotaxime is combined with Alendronic acid.]
[J01DC05, cefotetan, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotetan is combined with Alendronic acid.]
[J01DC07, cefotiam, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefotiam is combined with Alendronic acid.]
[J01DC01, cefoxitin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefoxitin is combined with Alendronic acid.]
[J01DD03, cefsulodin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefsulodin is combined with Alendronic acid.]
[J01DD02, ceftazidime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftazidime is combined with Alendronic acid.]
[J01DD07, ceftizoxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftizoxime is combined with Alendronic acid.]
[J01DD04, ceftriaxone, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Ceftriaxone is combined with Alendronic acid.]
[S01AA27, cefuroxime, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefuroxime is combined with Alendronic acid.]
[S01LA06, brolucizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Brolucizumab is combined with Alendronic acid.]
[J01XX09, daptomycin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Daptomycin is combined with Alendronic acid.]
[J01DB01, cephalexin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cephalexin is combined with Alendronic acid.]
[J01DB02, cephaloridine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefaloridine is combined with Alendronic acid.]
[J01DB03, cephalothin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefalotin is combined with Alendronic acid.]
[J01DB08, cephapirin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefapirin is combined with Alendronic acid.]
[J01DB09, cephradine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefradine is combined with Alendronic acid.]
[A16AX16, givosiran, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Givosiran is combined with Alendronic acid.]
[M01AH02, rofecoxib, The risk or severity of adverse effects can be increased when Rofecoxib is combined with Alendronic acid.]
[M01AC04, droxicam, The risk or severity of adverse effects can be increased when Droxicam is combined with Alendronic acid.]
[M02AA27, dexketoprofen, The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Alendronic acid.]
[P01BA01, chloroquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Chloroquine is combined with Alendronic acid.]
[N02BA07, ethenzamide, The risk or severity of adverse effects can be increased when Ethenzamide is combined with Alendronic acid.]
[M01AB08, etodolac, The risk or severity of adverse effects can be increased when Etodolac is combined with Alendronic acid.]
[M02AA06, etofenamate, The risk or severity of adverse effects can be increased when Etofenamate is combined with Alendronic acid.]
[C10AB09, etofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Etofibrate.]
[M01AE05, fenbufen, The risk or severity of adverse effects can be increased when Fenbufen is combined with Alendronic acid.]
[V08CA07, ferric ammonium citrate, Ferric ammonium citrate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB31, prussian blue insoluble, Prussian blue can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AB02, iron sucrose, Iron sucrose can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA05, ferrous chloride, Ferrous chloride can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA02, ferrous fumarate, Ferrous fumarate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA03, ferrous gluconate, Ferrous gluconate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA06, ferrous succinate, Ferrous succinate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA07, ferrous sulfate, Ferrous sulfate anhydrous can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01LA08, bevacizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Bevacizumab is combined with Alendronic acid.]
[B03AB10, ferric maltol, Ferric maltol can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BA01, cimetidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cimetidine is combined with Alendronic acid.]
[S03AA07, ciprofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ciprofloxacin is combined with Alendronic acid.]
[L01XA01, cisplatin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cisplatin is combined with Alendronic acid.]
[A12AA02, calcium glubionate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium glubionate anhydrous.]
[C10AB01, clofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Clofibrate.]
[J01GB12, arbekacin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Arbekacin is combined with Alendronic acid.]
[M01AX13, proquazone, The risk or severity of adverse effects can be increased when Proquazone is combined with Alendronic acid.]
[M04AC01, colchicine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Colchicine.]
[J01XB01, colistin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Colistin is combined with Alendronic acid.]
[J01DE02, cefpirome, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefpirome is combined with Alendronic acid.]
[L04AA13, leflunomide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Leflunomide.]
[A02AD04, hydrotalcite, The serum concentration of Alendronic acid can be decreased when it is combined with Hydrotalcite.]
[N02BA16, imidazole-2-hydroxybenzoate, The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Alendronic acid.]
[B01AC10, indobufen, The risk or severity of adverse effects can be increased when Indobufen is combined with Alendronic acid.]
[M01AH03, valdecoxib, The risk or severity of adverse effects can be increased when Valdecoxib is combined with Alendronic acid.]
[M01AH04, parecoxib, The risk or severity of adverse effects can be increased when Parecoxib is combined with Alendronic acid.]
[S01AD03, acyclovir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Acyclovir is combined with Alendronic acid.]
[M01AA06, kebuzone, The risk or severity of adverse effects can be increased when Kebuzone is combined with Alendronic acid.]
[A02BC05, esomeprazole, The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Esomeprazole.]
[H01CA02, nafarelin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Nafarelin.]
[M01AB09, lonazolac, The risk or severity of adverse effects can be increased when Lonazolac is combined with Alendronic acid.]
[M02AA31, loxoprofen, The risk or severity of adverse effects can be increased when Loxoprofen is combined with Alendronic acid.]
[J01DC08, loracarbef, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Loracarbef is combined with Alendronic acid.]
[A02AD02, magaldrate, The serum concentration of Alendronic acid can be decreased when it is combined with Magaldrate.]
[A06AD01, magnesium carbonate, The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium carbonate.]
[A03AA04, mebeverine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Mebeverine.]
[J05AF07, tenofovir disoproxil, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tenofovir disoproxil is combined with Alendronic acid.]
[S01XA18, cyclosporine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cyclosporine is combined with Alendronic acid.]
[C10AA07, rosuvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Rosuvastatin.]
[M02AA02, mofebutazone, The risk or severity of adverse effects can be increased when Mofebutazone is combined with Alendronic acid.]
[M01AX22, morniflumate, The risk or severity of adverse effects can be increased when Morniflumate is combined with Alendronic acid.]
[L01BC01, cytarabine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Cytarabine.]
[M01AH05, etoricoxib, The risk or severity of adverse effects can be increased when Etoricoxib is combined with Alendronic acid.]
[M01AX01, nabumetone, The risk or severity of adverse effects can be increased when Nabumetone is combined with Alendronic acid.]
[A07EC03, olsalazine, The risk or severity of adverse effects can be increased when Olsalazine is combined with Alendronic acid.]
[M01AE12, oxaprozin, The risk or severity of adverse effects can be increased when Oxaprozin is combined with Alendronic acid.]
[S03BA01, dexamethasone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Dexamethasone.]
[M05BA02, clodronic acid, The risk or severity of adverse effects can be increased when Alendronic acid is combined with Clodronic acid.]
[S01BC03, diclofenac, The risk or severity of adverse effects can be increased when Diclofenac is combined with Alendronic acid.]
[J05AD01, foscarnet, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Foscarnet is combined with Alendronic acid.]
[C03CA03, piretanide, The risk or severity of hypocalcemia can be increased when Piretanide is combined with Alendronic acid.]
[N02BA11, diflunisal, The risk or severity of adverse effects can be increased when Diflunisal is combined with Alendronic acid.]
[L04AX04, lenalidomide, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Lenalidomide is combined with Alendronic acid.]
[J05AE08, atazanavir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Atazanavir is combined with Alendronic acid.]
[N02BB04, propyphenazone, The risk or severity of adverse effects can be increased when Propyphenazone is combined with Alendronic acid.]
[M01AB14, proglumetacin, The risk or severity of adverse effects can be increased when Proglumetacin is combined with Alendronic acid.]
[L01EX01, sunitinib, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Sunitinib is combined with Alendronic acid.]
[S01BC05, ketorolac, The risk or severity of adverse effects can be increased when Ketorolac is combined with Alendronic acid.]
[N02BA06, salsalate, The risk or severity of adverse effects can be increased when Salsalate is combined with Alendronic acid.]
[R03AC12, salmeterol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Salmeterol.]
[H05BA01, salmon calcitonin, The risk or severity of hypocalcemia can be increased when Salmon calcitonin is combined with Alendronic acid.]
[C10AA01, simvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Simvastatin.]
[B05XA02, sodium bicarbonate, The serum concentration of Alendronic acid can be decreased when it is combined with Sodium bicarbonate.]
[M01AC02, tenoxicam, The risk or severity of adverse effects can be increased when Tenoxicam is combined with Alendronic acid.]
[D01BA02, terbinafine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Terbinafine.]
[P01AX02, emetine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Emetine.]
[N06AX14, tianeptine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Tianeptine.]
[C09AA02, enalapril, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Enalapril is combined with Alendronic acid.]
[M01AG02, tolfenamic acid, The risk or severity of adverse effects can be increased when Tolfenamic acid is combined with Alendronic acid.]
[C03CA04, torsemide, The risk or severity of hypocalcemia can be increased when Torasemide is combined with Alendronic acid.]
[M01AB04, zomepirac, The risk or severity of adverse effects can be increased when Zomepirac is combined with Alendronic acid.]
[L01XA02, carboplatin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Carboplatin is combined with Alendronic acid.]
[B01AC11, iloprost, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Iloprost.]
[A02BC02, pantoprazole, The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Pantoprazole.]
[C10AA04, fluvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Fluvastatin.]
[M01AC06, meloxicam, The risk or severity of adverse effects can be increased when Meloxicam is combined with Alendronic acid.]
[L04AD02, tacrolimus, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Tacrolimus is combined with Alendronic acid.]
[A02BA04, nizatidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Nizatidine is combined with Alendronic acid.]
[L02AE02, leuprolide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Leuprolide is combined with Alendronic acid.]
[C10AA03, pravastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Pravastatin is combined with Alendronic acid.]
[M05BA01, etidronic acid, The risk or severity of adverse effects can be increased when Alendronic acid is combined with Etidronic acid.]
[M01AE04, fenoprofen, The risk or severity of adverse effects can be increased when Fenoprofen is combined with Alendronic acid.]
[L04AA40, cladribine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cladribine is combined with Alendronic acid.]
[N02BG04, floctafenine, The risk or severity of adverse effects can be increased when Floctafenine is combined with Alendronic acid.]
[V03AZ01, ethanol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ethanol.]
[S01BC04, flurbiprofen, The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Alendronic acid.]
[S01AA07, framycetin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Framycetin is combined with Alendronic acid.]
[C03CA01, furosemide, The risk or severity of hypocalcemia can be increased when Furosemide is combined with Alendronic acid.]
[S01AA13, fusidic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Fusidic acid.]
[M01AG01, mefenamic acid, The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Alendronic acid.]
[S01AD09, ganciclovir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ganciclovir.]
[C10AB04, gemfibrozil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Gemfibrozil.]
[A12AA13, calcium citrate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium citrate.]
[A12AA10, calcium gluceptate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium glucoheptonate.]
[A12AA05, calcium lactate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium lactate.]
[A12AA30, calcium levulinate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium levulinate.]
[B05CB03, magnesium citrate, Magnesium citrate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC03, magnesium gluconate, Magnesium gluconate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A07EC02, mesalamine, The risk or severity of adverse effects can be increased when Mesalazine is combined with Alendronic acid.]
[M02AA26, nimesulide, The risk or severity of adverse effects can be increased when Nimesulide is combined with Alendronic acid.]
[C03AA03, hydrochlorothiazide, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Hydrochlorothiazide is combined with Alendronic acid.]
[M05BA07, risedronic acid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Risedronic acid.]
[R02AX02, ibuprofen, The risk or severity of adverse effects can be increased when Ibuprofen is combined with Alendronic acid.]
[L01CD01, paclitaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Paclitaxel.]
[S01BC01, indomethacin, The risk or severity of adverse effects can be increased when Indomethacin is combined with Alendronic acid.]
[S01LA04, ranibizumab, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Ranibizumab is combined with Alendronic acid.]
[C10AA06, cerivastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Cerivastatin is combined with Alendronic acid.]
[V03AB01, ipecac, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ipecac.]
[J05AF04, stavudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Stavudine.]
[J04AC01, isoniazid, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Isoniazid.]
[D10BA01, isotretinoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Isotretinoin.]
[P02CF01, ivermectin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ivermectin is combined with Alendronic acid.]
[S01AA24, kanamycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Kanamycin is combined with Alendronic acid.]
[H01AC01, somatropin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Somatotropin is combined with Alendronic acid.]
[A02AB01, aluminum hydroxide, The serum concentration of Alendronic acid can be decreased when it is combined with Aluminum hydroxide.]
[M02AA10, ketoprofen, The risk or severity of adverse effects can be increased when Ketoprofen is combined with Alendronic acid.]
[V03AC03, deferasirox, The risk or severity of gastrointestinal bleeding and gastrointestinal ulceration can be increased when Alendronic acid is combined with Deferasirox.]
[S01AA21, amikacin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amikacin is combined with Alendronic acid.]
[C10AA02, lovastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Lovastatin is combined with Alendronic acid.]
[B05XA11, magnesium chloride, Magnesium chloride can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G04BX01, magnesium hydroxide, The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium hydroxide.]
[A12CC10, magnesium oxide, The serum concentration of Alendronic acid can be decreased when it is combined with Magnesium oxide.]
[V04CC02, magnesium sulfate, Magnesium sulfate can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CX04, mannitol, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Mannitol is combined with Alendronic acid.]
[M02AA18, meclofenamic acid, The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Alendronic acid.]
[P01BC02, mefloquine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Mefloquine is combined with Alendronic acid.]
[J05AF05, lamivudine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Lamivudine.]
[L04AX03, methotrexate, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Methotrexate is combined with Alendronic acid.]
[C02AB01, methyldopa, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Methyldopa.]
[A03FA01, metoclopramide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Metoclopramide.]
[N02BB03, aminopyrine, The risk or severity of adverse effects can be increased when Aminophenazone is combined with Alendronic acid.]
[J01AA08, minocycline, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Minocycline.]
[C01BD01, amiodarone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Amiodarone.]
[J01DD06, moxalactam, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Latamoxef is combined with Alendronic acid.]
[L01EX03, pazopanib, The risk or severity of jaw osteonecrosis and anti-angiogenesis can be increased when Pazopanib is combined with Alendronic acid.]
[J05AJ01, raltegravir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Raltegravir.]
[N07BB04, naltrexone, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Naltrexone.]
[M02AA12, naproxen, The risk or severity of adverse effects can be increased when Naproxen is combined with Alendronic acid.]
[L01CD02, docetaxel, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Docetaxel.]
[L02BG04, letrozole, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Letrozole.]
[S03AA01, neomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Neomycin is combined with Alendronic acid.]
[J02AA01, amphotericin B, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Amphotericin B is combined with Alendronic acid.]
[S01AA23, netilmicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Netilmicin is combined with Alendronic acid.]
[J05AB11, valacyclovir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Valaciclovir is combined with Alendronic acid.]
[C10AD02, niacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Niacin is combined with Alendronic acid.]
[M02AA17, niflumic acid, The risk or severity of adverse effects can be increased when Niflumic acid is combined with Alendronic acid.]
[C02DD01, nitroprusside, Nitroprusside can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AE02, norfloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Norfloxacin.]
[S02AA16, ofloxacin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ofloxacin.]
[A02BC01, omeprazole, The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Omeprazole.]
[M05BA08, zoledronic acid, The risk or severity of adverse effects can be increased when Zoledronic acid is combined with Alendronic acid.]
[V08CB01, ferumoxsil, Ferumoxsil can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01BC02, oxyphenbutazone, The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Alendronic acid.]
[J04AB30, capreomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Capreomycin is combined with Alendronic acid.]
[A07AA06, paromomycin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Paromomycin is combined with Alendronic acid.]
[M01CC01, penicillamine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Penicillamine.]
[G04BX06, phenazopyridine, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Phenazopyridine is combined with Alendronic acid.]
[M02AA01, phenylbutazone, The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Alendronic acid.]
[A02BC06, dexlansoprazole, The therapeutic efficacy of Alendronic acid can be decreased when used in combination with Dexlansoprazole.]
[N03AB02, phenytoin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Phenytoin is combined with Alendronic acid.]
[J05AB12, cidofovir, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cidofovir is combined with Alendronic acid.]
[C10AA05, atorvastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Atorvastatin.]
[J05AE01, saquinavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Saquinavir.]
[C09CA02, eprosartan, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Eprosartan.]
[S01BC06, piroxicam, The risk or severity of adverse effects can be increased when Piroxicam is combined with Alendronic acid.]
[J01DD16, cefditoren, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Cefditoren is combined with Alendronic acid.]
[J05AE03, ritonavir, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Ritonavir is combined with Alendronic acid.]
[C10AA08, pitavastatin, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Pitavastatin.]
[C01BA02, procainamide, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Procainamide.]
[L01XB01, procarbazine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Procarbazine.]
[C10AB05, fenofibrate, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Fenofibrate.]
[N01AX10, propofol, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Propofol.]
[H03BA02, propylthiouracil, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Propylthiouracil is combined with Alendronic acid.]
[R03DC03, montelukast, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Montelukast is combined with Alendronic acid.]
[A02BA02, ranitidine, The risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Ranitidine.]
[N02BA05, salicylamide, The risk or severity of adverse effects can be increased when Salicylamide is combined with Alendronic acid.]
[A07EC01, sulfasalazine, The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Alendronic acid.]
[S01BC08, salicylic acid, The risk or severity of adverse effects can be increased when Salicylic acid is combined with Alendronic acid.]
[J01GB08, sisomicin, The risk or severity of nephrotoxicity and hypocalcemia can be increased when Sisomicin is combined with Alendronic acid.]
[M01AE11, tiaprofenic acid, The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Alendronic acid.]
[C03CC01, ethacrynic acid, The risk or severity of hypocalcemia can be increased when Etacrynic acid is combined with Alendronic acid.]
[A12AA11, calcium pangamate, The serum concentration of Alendronic acid can be decreased when it is combined with Calcium pangamate.]
